Related Experiment Videos
Immunologic and surgical developments in cardiac transplantation.
Current Opinion in Cardiology
|March 1, 1993
Summary
Cardiac transplant survival may improve with HLA typing and new immunosuppressants like FK 506. Novel therapies show promise for graft rejection, while ganciclovir aids cytomegalovirus prevention in transplant patients.
Area of Science:
- Cardiology
- Immunology
- Transplantation Medicine
Background:
- Cardiac transplantation faces significant challenges including graft rejection and infection.
- Current clinical strategies primarily focus on managing these post-transplant complications.
Purpose of the Study:
- To review advancements in cardiac transplantation, focusing on improving patient survival and managing complications.
- To evaluate the efficacy of novel immunosuppressive agents and prophylactic treatments.
Main Methods:
- Review of retrospective analyses and clinical trials concerning cardiac transplantation.
- Examination of immunologic interventions such as HLA typing, FK 506, monoclonal antibodies, and ganciclovir prophylaxis.
Main Results:
- Prospective HLA typing may enhance patient survival, mirroring practices in renal transplantation.
- FK 506 demonstrates benefits over cyclosporine in cardiac transplant trials.
- Novel immunotherapies show potential for treating allograft rejection.
- Prophylactic ganciclovir is effective in preventing cytomegalovirus disease in seropositive recipients.
Conclusions:
- Optimizing immunosuppression and employing advanced immunologic strategies are crucial for successful cardiac transplantation.
- Further research is needed to prevent primary cytomegalovirus infection in seronegative transplant patients.